cancer drug news from FierceBiotech
News
ALSO NOTED: Genta places notes;Vaccine research blasts off; and much more...
> Genta announced that it has struck definitive agreements with investors to place senior secured convertible notes due in 2010 totaling in aggregate up to $40 million in gross proceeds before Read more...
Medarex shares dented on analysts' skepticism
Investors dented the value of Medarex shares after analysts doused its recent claims concerning its late-stage cancer drug ipilimumab with cold water. BMO Capital Market's Jason Zhang says that Read more...
Pfizer rumored to be eyeing MediGene buyout
Rumors are swirling that Pfizer is looking to take over the German biotech Read more...
FDA staffers say that Eisai sedative appears safe
FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in Read more...
Medarex shares slide on news of drug app delay
Shares of Medarex slipped seven percent this morning as investors digested Friday's announcement that its application for a new cancer drug will be delayed into 2009. The developer says that the FDA Read more...
SPOTLIGHT: CuraGen sells Belinostat stake to TopoTarget
CuraGen Corporation has sold its stake in Belinostat to TopoTarget for $39 million upfront in a combination of cash and stock. TopoTarget will now take full control of the cancer drug's development. Read more...
Optimistic Dendreon revs up second program
Dendreon is making bullish noises about its development efforts. The CMO of the Seattle biotech says that Provenge will deliver positive new data to the FDA on the delayed cancer therapy Provenge Read more...
In survival mode, Genta hunts for funds
NJ Biz examines Genta, which has gone into survival mode as it seeks a way to gain FDA approval of its lead cancer therapy, Genasense. The FDA turned thumb's down on the therapy in 2004, and the Read more...
Eisai drug flunks Parkinson's trial
Eisai's has halted development of Perampanel (E2007) for Parkinson's after the drug failed a late-stage trial. Compared with placebo, E2007 didn't show a significant difference in the primary Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends